-
Mashup Score: 12
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more than 5…
Source: www.nejm.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up. Methods Participants received an average dose of 0.5 × 106 cells/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated. Results Seventy-four participants enrolled and had a median follow-up of 65.4 months. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 21.0% and 49.1%, with progressive flattening of the survival curves over time. Patients with complete response (CR
Source: jhoonline.biomedcentral.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Frontiers | Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference - 17 hour(s) ago
Chimeric antigen receptor (CAR) -T cell therapy has entered the breakthrough era, characterized by a blend of therapeutic opportunities and challenges. With …
Source: www.frontiersin.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma - 17 hour(s) ago
Abstract. Several second- and third-line immunotherapeutic options for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant are directed against the B-cell antigen CD19. The anti-CD19 monoclonal antibody tafasitamab, paired with the immunomodulator lenalidomide, mediates antibody-dependent cellular toxicity and cellular phagocytosis; the antibody–drug conjugate loncastuximab tesirine delivers the DNA-cross-linking agent tesirine via CD19 binding and internalization; and CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) products are engineered from autologous T cells. While CD19 expression is assessed at diagnosis, clinically relevant thresholds of CD19 expression—which may not be detectable with current routine methodologies—have not been defined and may vary between CD19-directed treatment modalities. Determining optimal treatment sequencing strategies with CD19-directed therapy has been hampered by the
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Chimeric antigen receptor T-cell (CAR-T) therapy is effective in the treatment of relapsed/refractory acute B-lymphoblastic leukemia (R/R B-ALL); however, patients who receive CAR-T therapy are predisposed to infections, with considerable detrimental effects on long-term survival rates and the quali …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Objectives Our aim was to describe the frequency and severity of infectious complications after chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL). Method…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease - 5 day(s) ago
Nature Communications – Graft-versus-Host disease is a major complication after allogeneic bone marrow transplantation and is ameliorated by adoptively transferred donor regulatory T cells. Here,…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Bilateral Cytomegalovirus Retinitis After Chimeric Antigen Receptor T-cell Therapy for B-cell Lymphoma - 5 day(s) ago
Cytomegalovirus (CMV) retinitis is commonly associated with immunosuppression and can cause irreversible vision loss. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as an effective…
Source: www.cureus.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies - 5 day(s) ago
Studies have compared chimeric antigen receptor (CAR) T-cell therapies and salvage chemotherapy in relapsed/refractory large B-cell lymphoma (LBCL) patients, but further evidence of their relative …
Source: www.tandfonline.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK - 7 day(s) ago
Editor—Autologous chimeric antigen receptor (CAR)-T cells are genetically modified to specifically recognise and eliminate tumour cells expressing selected antigens. In the UK, CAR-T cell therapy was first approved for relapsed/refractory large B cell lymphoma and relapsed/refractory acute lymphoblastic leukaemia in 2018.1 Activated CAR-T cells trigger an inflammatory reaction responsible for the two most common toxicities associated with the therapy, namely, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Source: www.bjanaesthesia.orgCategories: General Medicine News, Onc News and JournalsTweet
CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia | New England Journal of Medicine https://t.co/XyoOM9yKVD